Introduction {#S0001}
============

As a result of effective screening, the incidence rate of cervical cancer has decreased dramatically in developed countries. However, cervical cancer remains a serious issue for women in developing countries such as China.[@CIT0001] Lymph node metastases are the most important transport pathways of cervical cancer. It commonly occurs in internal iliac, external iliac, obturator, and common iliac lymph nodes.[@CIT0002]--[@CIT0004]

Mesorectum metastatic lymph nodes (MLNs) are very common in rectum cancer patients, and total mesorectal excision has become the standard approach in the surgery of rectum cancer. For cervical cancer, mesorectum MLNs are rare and literature reports are limited.[@CIT0002],[@CIT0005] In this study, we retrospectively analyzed the characteristics and survival of patients with mesorectum MLNs in our institute. To our knowledge, this is the first report on the incidence of mesorectum MLNs from cervical cancer and the first report on the survival of these patients.

Materials and Methods {#S0002}
=====================

Patients {#S0002-S2001}
--------

We searched the electronic database of our institute and retrospectively reviewed records for cervical cancer patients between January 2011 and December 2015. We identified 1194 consecutive patients with International Federation of Gynecology and Obstetrics (FIGO) stages IA--IVA cervical cancer who were treated with definitive radiotherapy or concurrent chemoradiotherapy (CCRT). Of them, 10 patients had mesorectum MLNs before treatment. The criteria for MLNs were as follows: (1) a short diameter longer than 1 cm on computed tomography (CT) or magnetic resonance (MR) images and (2) confirmed by positron emission tomography/computed tomography (PET/CT). The mesorectum region was the area within the mesorectum, with an upper bound in the level of the lower edge of the sacroiliac joints. Involved lymph nodes in the mesorectum region were defined as mesorectum MLNs. Lymph nodes above the lower edge of the sacroiliac joints were grouped into presacral nodes.

The clinical characteristics of all patients (including patients with or without mesorectum MLNs) were collected, including age, histology, FIGO stage, the number and location of regional MLNs, the diagnostic modalities for mesorectum MLNs, and treatment information.

Treatment {#S0002-S2002}
---------

Patients were treated with CCRT as described previously.[@CIT0006],[@CIT0007] All patients received CT simulation. Gross tumor volume (GTV) and clinical target volume (CTV) were contoured on the CT slices. The GTV covered the regional MLNs, and the CTV included the primary tumor, cervix, parametrium, and pelvic lymph node regions. The para-aortic lymph node region was included in the CTV for patients with para-aortic MLNs or high risk of para-aortic region failure. For patients with mesorectum MLNs, part of the mesorectum region was also included in the CTV. A margin of 5 mm was added to the GTV to generate the planning gross tumor volume (PGTV). The CTV was expanded 6--10 mm to create the planning clinical target volume (PCTV). A dose of 50.4 Gy in 28 fractions was prescribed to the planning target volume (PTV), and 59--61 Gy was delivered to the MLNs with a simultaneous-integrated boost (SIB) with intensity-modulated radiation therapy (IMRT). High-dose-rate intracavitary brachytherapy (ICBT) began after 3 weeks of external beam radiotherapy. A dose of 30--36 Gy in 5--7 fractions was delivered to point A. The first-line regimen of concurrent chemotherapy was cisplatin 30--40 mg/m^2^ weekly.

Follow-Up and Statistics {#S0002-S2003}
------------------------

As prescribed previously,[@CIT0006],[@CIT0007] patients had gynecological examinations and pelvic MRI/CT 1 month after treatment. Subsequently, patients had follow-up examinations every 3 months for the next 2 years, every 6 months for 3--5 years, and once a year for 5 years after that. For patients with suspicious recurrence tumor, biopsy and/or were recommended.

Overall survival (OS), disease-free survival (DFS), and local control (LC) were estimated using the Kaplan--Meier method. The significance of difference was examined with a log-rank test. Cox's regression model was used for multivariate analysis. We also compared the characteristics of patients with and without mesorectum MLNs with a continuity-correction Chi-square test (histology, para-aortic MLNs, common iliac MLNs, and treatment approach), Fisher's exact test (treatment approach), *t*-tests (age and tumor size), and Mann--Whitney test (FIGO stage). Statistical analysis was performed using SPSS v.22.0. Difference was considered statistically significant at two-sided p \< 0.05.

Results {#S0003}
=======

The incidence of mesorectum MLNs was 0.8% (10/1194) for cervical cancer patients. The detailed clinical characteristics and survival of patients with mesorectum MLNs are summarized in [Table 1](#T0001){ref-type="table"}. The MRI T2 and diffusion-weighted imaging (DWI) images of patient 10 in [Table 1](#T0001){ref-type="table"} are shown in [Figure 1](#F0001){ref-type="fig"}, and the PET/CT images of patient 4 in [Table 1](#T0001){ref-type="table"} are shown in [Figure 2](#F0002){ref-type="fig"}. The median age was 50 years (range, 37--63 years). Nine patients had squamous cell carcinoma, and 1 patient had adenocarcinoma. Three patients had stage IIB, 4 patients had stage IIIB, and 3 patients had stage IVA disease. The incidence rates for patients with FIGO stages I, II, III, and IVA disease were 0% (0/154), 0.4% (3/826), 2.0% (4/205), and 33.3% (3/9), respectively. In patients with FIGO III-IV disease and pelvic MLNs, the incidence of mesorectum MLNs was 3.3% (7/214) and 2.8% (10/353), respectively. The median size of the tumor was 6 cm (range, 3--8 cm). Mesorectum MLNs were diagnosed by PET/CT in 3 patients, MRI in 4 patients, and contrast-enhanced computed tomography (CT) in 3 patients. A total of 16 mesorectum MLNs were found in these 10 patients. The numbers of mesorectum MLNs were 1 in 6 patients, 2 in 3 patients, and 4 in 1 patient. Eight patients had para-aortic MLNs, and 8 patients had common iliac MLNs. All 10 patients suffered with bilateral pelvic MLNs, and 5 of them had presacral MLNs. All 10 patients completed radiotherapy. The fractionated doses of ICBT were 36 Gy in 6 fractions in 5 patients, 30 Gy in 5 fractions in 4 patients, and 34 Gy in 6 fractions in 1 patient. Concurrent chemotherapy was administered in 9 patients. Of them, 5 times of cisplatin were performed in 5 patients, 4 times in 2 patients, and 3 times in 2 patients.Table 1The Clinical Characteristics and Survival of Patients with Mesorectum MLNsNo.Age (Years Old)HistologyFIGO StageTumor Size (cm)Characteristics of Mesorectum MLNsPara-Aortic MLNsCommon iliac MLNsPresacral MLNsTreatment ApproachesSites of FailureTime to Failure (Months)Time to Death (Months)NumberSize (cm)Diagnostic Modalities140SCCIIB611.2PET/CTYesYesNoCCRTPelvic recurrence + pulmonary metastases5.739.77250SCCIIIB5.511MRINoYesNoCCRTPulmonary metastases4.7710.90355SCCIIIB611.3MRIYesYesNoCCRTPelvic recurrence + pulmonary metastases + mesenteric MLNs7.8323.83458SCCIVA (Sigmoid colon invasion)621.1PET/CTYesNoYesCCRTSplenic hilar MLNs12.0728.43548SCCIIIB511.1CTYesYesYesCCRTPR0.009.50663SCCIIB821.4CTYesYesYesRTPR0.0010.43750AdenocarcinomaIIB6.541.2MRI+DWIYesYesYesCCRTPR0.005.07850SCCIIIB321.3PET/CTYesYesYesCCRTPR0.007.27937SCCIVA (Rectum invasion)712.2CTYesYesNoCCRTPR0.0010.531043SCCIVA (Rectum invasion)411.1MRI+DWINoNoNoCCRTMediastinal MLNs6.5320.90[^2] Figure 1The T2 weighted-MR (**A**) and diffusion-weighted imaging (DWI, **B**) images of a patient with mesorectum metastatic lymph node.Figure 2Positron emission tomography/computed tomography (PET/CT, **A** and **B**), T1-weighted MR (**C**) and T2-weighted MR (**D**) images of a patient with mesorectum metastatic lymph node.

As shown in [Table 2](#T0002){ref-type="table"}, mesorectum MLNs were associated with more advanced stages (p \<0.001), larger tumor size (p = 0.002), higher incidence rates of para-aortic MLNs (p \<0.001), and common iliac MLNs (p \<0.001) than in patients without mesorectum MLNs. Age, histology, and treatment of these two groups were similar.Table 2The Clinical Characteristics of Patients with and Without Mesorectum MLNsCharacteristicsWith Mesorectum MLNs (n = 10)Without Mesorectum MLNs (n = 1184)pnPercentage (%)nPercentage (%)Median age (years old)50 (range, 37--63)54 (range, 23--88)0.271Histology SCC990105689.21.000 Non-SCC11012810.8FIGO stage I0015413.0\<0.001 II33082369.5 III44020117.0 IVA33060.5Median tumor size (cm)6 (range, 3--8)4 (range, 0--12)0.002Para-aortic MLNs Yes880.0736.2\<0.001 No220.0111193.8Common iliac MLNs Yes880.0887.4\<0.001 No220.0109692.6Bilateral pelvic MLNs Yes10100.019916.8\<0.001 No00.098583.2Treatment approach RT110.017614.81.000 CCRT990.0100885.2[^3]

The median follow-up periods were 26.2 months (range, 1.2--74.1 months) for the whole cohort (1194 patients) and 10.48 months (range, 5.07--28.43 months) for patients with mesorectum MLNs (10 patients). All patients experienced treatment failure and died during follow-up. The median OS was 10.43 months (95% confidence interval (CI): 9.25--11.61 months). The 1-year OS, DFS, and LC rates were 30.0%, 10.0%, and 30%, respectively. The 2-year OS, DFS, and LC rates were 10%, 0%, and 30%, respectively. The OS, DFS, and LC curves of patients with mesorectum MLNs are shown in [Figure 3](#F0003){ref-type="fig"}.Figure 3The overall survival (OS), disease-free survival (DFS), and local control (LC) curve of patients with mesorectum metastatic lymph nodes.

For 10 patients with mesorectum MLNs, 5 patients acquired a complete clinical response (CR), and the other 5 patients had a partial clinical response (PR) after treatment. Three of the 5 patients with acquired CR experienced distant metastases, and the other 2 patients had concurrent local recurrence and distant failure. The sites of distant failure included pulmonary metastases (2 patients), mesenteric MLNs (1 patient), mediastinal MLNs (1 patient), and splenic hilar MLNs (1 patient). The pelvic failure and distant failure rates were 70.0% and 11.6% (p\<0.001), 50% and 15.3% (p\<0.001) in patients with/without mesorectum MLNs, respectively.

Univariate analysis showed that age, histology, tumor size, FIGO stage, mesorectum MLNs, para-aortic MLNs, pelvic MLNs, common iliac MLNs, bilateral pelvic MLNs and concurrent chemotherapy were prognostic factors of OS. After multivariate analysis, mesorectum MLNs were an independent prognostic factor of OS (hazard ratio, HR 4.0, 95% CI 1.8--9.1, p=0.001). The details of univariate and multivariate analysis are shown in [Table 3](#T0003){ref-type="table"}.Table 3Univariate and Multivariate Analysis for Patients with Cervical CancerCharacteristicsNUnivariate AnalysisMultivariate Analysis3-year OSpHR (95% CI)pAge \<65105584.6%0.0141 ≥6513975.1%1.7 (1.1--2.7)0.011Histology SCC106584.9%\<0.0011 Non-SCC12971.5%2.3 (1.6--3.5)\<0.001Tumor size \<4cm47790.3%\<0.0011 ≥4cm71779.0%1.7 (1.2--2.5)0.004FIGO stage I15490.8%\<0.0011 II82685.3%1.6 (0.8--3.1)0.144 III20572.7%2.8 (1.4--5.7)0.003 IVA921.4%1.8 (0.5--6.9)0.362Mesorectum MLNs Yes11840%\<0.0014.0 (1.8--9.1)0.001 No1084.4%1Para-aortic MLNs Yes8144.0%\<0.0011.8 (1.1--2.8)0.017 No111386.3%1Pelvic MLNs Yes35369.3%\<0.0012.5 (1.7--3.7)\<0.001 No84189.2%1Common iliac MLNs Yes9652.0%\<0.0011.5 (0.95--2.3)0.082 No109886.1%1Bilateral pelvic MLNs Yes20963.5%\<0.0011.0 (0.7--1.6)0.938 No98587.6%1Treatment approach RT17774.4%0.0011 CCRT101785.0%0.6 (0.4--0.9)0.010[^4]

For the 73 patients with para-aortic MLNs, the 2-year OS, DFS, and LC rates were 51.3%, 40.0%, and 53.3%, respectively, which was also much higher than in patients with mesorectum MLNs (p = 0.004 for OS rate, 0.001 for DFS rate, and 0.069 for LC rate). For nine patients with FIGO IVA disease, the median OS was 28.43 months (95% CI 13.0--43.9 months), which was significantly higher than that of patients with mesorectum MLNs (p=0.009).

In the present study, there were seven patients with rectum invasion. Three of them had mesorectum MLNs and the other four did not have. In patients with and without mesorectum MLNs, the mean DFS was 3.5 months (95% CI 0--13.0 months) and 9.5 months (0.7--37.9 months, p=0.171), respectively. And, the mean LC was 19.0 months (95% CI 3.8--34.2 months) and 29.1 months (11.3--46.9 months, p=0.806), respectively. There was a trend that patients with mesorectum MLNs had worse DFS and LC. However, as the number of patients was small, the differences were not significant.

Only 1 patient (patient No. 4 in [Table 1](#T0001){ref-type="table"}) developed grade 3 chronic enteritis, and no other grade 3 or greater chronic toxicity was observed.

Discussion {#S0004}
==========

Mesorectum MLNs from cervical cancer are rare and studies are limited. In 2016, Barrett et al reported two patients with mesorectum MLNs from advanced cervical cancer. These two patients were also treated with radiotherapy.[@CIT0005] As we know, it is the first report on mesorectum MLNs from cervical cancer. Previously, we evaluated the regional lymph nodes of 244 stage IIB cervical cancer patients and found that 1 patient had positive mesorectum MLNs and 1 patient had suspicious mesorectum MLNs.[@CIT0002] In our study, the incidence rate of mesorectum MLNs was 0.8% (10/1194). To our knowledge, this was the first report on the incidence of mesorectum MLNs in cervical cancer patients.

The pathway of mesorectum MLNs from cervical cancer is unclear. Probably, it is associated with invasion of the rectum or mesorectum. For patients with FIGO stages I, II, III, and IVA cervical cancer, the incidence rates of mesorectum MLNs were 0%, 0.4%, 2.0%, and 33.3%, respectively, in our study, and mesorectum MLNs were associated with more advanced FIGO stage (p \<0.001). For patients with FIGO IVA disease, mesorectum MLNs were not rare, especially in patients with rectum mucosa invasion. According to the 2009 FIGO staging system,[@CIT0008] when the tumor invades the mesorectum or rectum, and the rectum mucosa is not involved, the tumor is not defined as FIGO stage IVA disease. It was difficult for us to identify the mesorectum invasion accurately on CT, MRI, and PET/CT, and we could not analyze the association between mesorectum invasion and mesorectum MLNs. We also found that patients with mesorectum MLNs were more likely to have para-aortic MLNs (p \<0.001), common iliac MLNs (p\<0.001), and bilateral pelvic MLNs (p \<0.001). Refluent lymphatic drainage from the superior mesenteric artery and iliac lymph node regions might be another pathway of mesorectum lymph nodes metastasis. It was reported that the incidence rate of presacral MLNs was just 5% (6/114) in patients with pelvic MLNs.[@CIT0009] In the study by Liu Z, only 1 of 244 patients (0.4%) with FIGO stage IIB cervical cancer had positive presacral MLNs.[@CIT0002] In the present study, 5 of the 10 patients (50%) with mesorectum MLNs had presacral MLNs. It indicated the association between mesorectum MLNs and presacral MLNs in patients with cervical cancer. Considering FIGO stage is closely related with MLNs, the association between mesorectum MLNs and advanced FIGO stage/multiple MLNs should be interpreted with caution.

All patients with mesorectum MLNs experienced treatment failure and died during follow-up. The median OS was just 10.43 months (95% CI: 9.25--11.61 months). The survival was even much lower than patients with para-aortic MLNs and patients with FIGO stage IVA disease. Para-aortic MLNs and FIGO IVA disease were considered to be the worst prognostic factors for local advanced cervical cancer. This is also the first report on the survival of patients with mesorectum MLNs. The FIGO staging system[@CIT0008] did not definitely define that mesorectum MLNs should be classified with regional MLNs or distant metastases. The survival of cervical cancer patients with mesorectum MLNs was poor.

In this study, mesorectum MLNs were diagnosed by imaging. It was reported that the sensitivity of CT, MRI, and PET was 50--59%, 56--59%, and 76--82%, respectively, and the specificity was 91--92%, 90--91%, and 94--95%, also, respectively.[@CIT0010],[@CIT0011] Considering the comparatively low sensitivity of MLNs in these imaging modalities, we might miss some occult MLNs and underestimate the incidence rate of mesorectum MLNs. However, the specificity of all three imaging modalities was higher than 90%,[@CIT0010],[@CIT0011] and the misdiagnosis rate of our study was low. Transrectal fine needle aspiration cytology is an approach to confirm suspicious mesorectum MLNs. And studies based on histology are more accurate in the diagnose of mesorectum MLNs. This study demonstrated that mesorectum was an independent factor of OS for patients with cervical cancer. Even so, mesorectum MLNs were not the only reason for the poor survival of these 10 patients in the present study. The other factors, such as advanced stage, para-aortic MLNs and multiple MLNs, etc., also contributed to the poor survival.

Conclusion {#S0005}
==========

Mesorectum MLNs from cervical cancer are rare. And, the survival of patients with mesorectum MLNs was poor after definitive concurrent chemoradiotherapy, although the mesorectum MLNs were boosted to 59--61Gy.
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